Oncolytic herpes simplex virus tumor targeting and neutralization escape by engineering viral envelope glycoproteins
Oncolytic herpes simplex viruses (oHSVs) have been approved for clinical usage and become more and more popular for tumor virotherapy. However, there are still many issues for the oHSVs used in clinics and clinical trials. The main issues are the limited anti-tumor effects, intratumor injection, and...
Сохранить в:
Главные авторы: | , , , , , , , , , , , , , |
---|---|
Формат: | |
Опубликовано: |
Taylor & Francis Group,
2018-01-01T00:00:00Z.
|
Предметы: | |
Online-ссылка: | Connect to this object online. |
Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|
Internet
Connect to this object online.3rd Floor Main Library
Шифр: |
A1234.567 |
---|---|
Копировать 1 | Доступно |